Quantcast

Latest Avastin Stories

46cc534a0fae79d6b039eef9687929061
2009-12-20 13:25:50

Up to 25% of cancer patients develop metastases in the brain "“ often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious. Now a research team led by neurologist Dr. Frank Winkler of LMU Munich has followed, in real time, the steps that lead some tumor cells to establish metastases, while others fail to form new tumors. The team also discovered...

2009-12-17 10:30:00

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom. The new Special European...

2009-12-15 07:00:00

WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer. The new Special European Physician & Payer Forum report entitled European Trends in Targeted Therapies in...

2009-12-07 08:00:00

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain. The new Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in...

2009-11-17 12:22:08

NewYork-Presbyterian/Weill Cornell study opens blood-brain barrier to deliver high-dose chemotherapy to malignant brain tumors; may avoid common side effects of systemic chemotherapy Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy,...

2009-10-10 07:50:30

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in the American Journal of Ophthalmology, is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial...

2009-09-28 08:41:00

WALTHAM, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Chugai's Avastin is prescribed by the majority of surveyed oncologists for glioblastoma multiforme, non-small-cell lung cancer and breast cancer. Additionally, the drug is prescribed by all surveyed oncologists for colorectal cancer. However, the high cost of Avastin remains a barrier to treatment for nearly...

2009-09-07 13:50:38

U.S. researchers say the drug Avastin may improve the survival rates for recurrent glioblastomas -- the most aggressive type of primary brain tumor. Senior author Dr. Timothy Cloughesy, director of the Neuro-Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center says the drug helped improve survival rates in the case of glioblastomas that had recurred so dramatically, the U.S. Food and Drug Administration accelerated approval of this use of the...

2009-09-02 23:45:00

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred. Patients with recurrent glioblastoma have a grim prognosis, and conventional treatments were typically limited to largely ineffective and highly toxic chemotherapies. Only about 5 percent of patients respond to further treatment "“ meaning...

2009-08-03 07:12:29

UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will shrink when treated by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy. Bronnie McNabb, 57, considers himself a lucky man. When his aggressive brain cancer returned after chemotherapy and...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related